Our research also found that, although it is statistically non-significant, patients with LC with a high PECAM-1 expression had a longer overall survival period, which may be related to the effect of PECAM-1 on the tumor immune microenvironment, promoting the transport of immune cells and enhancing the role of immune cells. This evidence concerns the gene PECAM1 and laryngotracheoesophageal cleft.